Bydureon / Byetta (exenatide) 10 mg, AstraZeneca
Article: 4987162000216
In Stock
Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,10 while the immediate-acting formulation is approved only for adult patients.
- Commercial name:Byetta
- Сhemical name:Exenatide
- Dosage:10 mg
No reviews yet